RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World
Saturday, November 7, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis Adela Castro, MD – UT Southwestern
9:00 AM – 11:00 AM ET
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92 Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
9:00 AM – 11:00 AM ET
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD Renske Hebing, MSc – Reade
9:00 AM – 11:00 AM ET
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis Jonathan Kay, MD – University of Massachusetts Medical School
9:00 AM – 11:00 AM ET
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study Leslie R. Harrold, MD, MPH – Corrona, LLC
9:00 AM – 11:00 AM ET
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness Yoshiya Tanaka, MD, PhD – University of Occupational and Environmental Health, Japan
9:00 AM – 11:00 AM ET
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety mitsumasa kishimoto, MD – Kyorin University School of Medicine
9:00 AM – 11:00 AM ET
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands Elise van Mulligen, MSc – Erasmus MC
9:00 AM – 11:00 AM ET
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis Ulf Müller-Ladner, MD – JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol
9:00 AM – 11:00 AM ET
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy Anthony J. Cordisco, MA – Perelman School of Medicine
9:00 AM – 11:00 AM ET
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis Akhil Sood, MD – University of Texas Medical Branch
9:00 AM – 11:00 AM ET
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort Mohammad Movahedi, MD, PhD – Toronto General Hospital Research Institute, University Health Network
9:00 AM – 11:00 AM ET
Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study Sergio Schwartzman, MD – Self Employed 72nd Street Medical Associates
9:00 AM – 11:00 AM ET
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data Kieran Murray, MD, -None- – Saint Vincent's University Hospital
9:00 AM – 11:00 AM ET
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab Janet Pope, MD, FRCPC, MPH – University of Western Ontario
9:00 AM – 11:00 AM ET
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US Simon Helfgott, MD – BWH- HMS
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic Rishi Gupta, MBBS, BSc – University College London Hospital
9:00 AM – 11:00 AM ET
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients Deepan S. Dalal, MD, MPH – Brown University School of Medicine
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia Geoffrey Littlejohn, MBBS – Geoffrey Littlejohn P/L
9:00 AM – 11:00 AM ET
Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis Miriam Retuerto, MD – Hospital universitario 12 de octubre
9:00 AM – 11:00 AM ET
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar huifeng Yun, MD, PhD – UAB
9:00 AM – 11:00 AM ET
High Remission Rates in RA – Real Life Data from Bariticinib Sara Bayat, MD – University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology
9:00 AM – 11:00 AM ET
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry Vijaya Rivera Teran, MD – Colegio Mexicano de Reumatologia
9:00 AM – 11:00 AM ET
Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study Janet Pope, MD, FRCPC, MPH – University of Western Ontario
9:00 AM – 11:00 AM ET
Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis Jasvinder Singh, MD, MPH – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study Leslie R. Harrold, MD, MPH – Corrona, LLC
9:00 AM – 11:00 AM ET
Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials Niall Jones, MD, FRCP – Rheumatology Associates
9:00 AM – 11:00 AM ET
Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study Paul Emery, MD, FRCP, MA, FMedSci – University of Leeds
9:00 AM – 11:00 AM ET
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Thomas Huizinga, MD, PhD – Leiden University Medical Center
9:00 AM – 11:00 AM ET
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study Stanley B. Cohen, MD – Metroplex Clinical Research Center
9:00 AM – 11:00 AM ET
International Comparison of Japanese and US Cross Country Utilization of RA Medications Hisashi Yamanaka, MD – Sanno Medical Center
9:00 AM – 11:00 AM ET
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort Mohammad Movahedi, MD, PhD – Toronto General Hospital Research Institute, University Health Network
9:00 AM – 11:00 AM ET
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort Mohammad Movahedi, MD, PhD – Toronto General Hospital Research Institute, University Health Network
9:00 AM – 11:00 AM ET
PROSARA - A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany Eugen Feist, MD – Helios Department of Rheumatology
9:00 AM – 11:00 AM ET
Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics Andrea de Diego Sola, MD – Hospital Universitario Donostia
9:00 AM – 11:00 AM ET
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry Jeffrey R R. Curtis, MD, MS, MPH – University of Alabama at Birmingham
